<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00663455</url>
  </required_header>
  <id_info>
    <org_study_id>Recaltox-1</org_study_id>
    <nct_id>NCT00663455</nct_id>
  </id_info>
  <brief_title>Randomized Study to Reduce Calcineurininhibitor Toxicity in Pediatric and Adolescent Kidney Transplant Recipients</brief_title>
  <acronym>Recaltox</acronym>
  <official_title>A Multicenter, Randomized, Parallel-group, Trial to Reduce Toxicity of Calcineurininhibitor-therapy in Steroid-free Longterm Immunosuppression in Pediatric and Adolescent Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a safe reduction of cyclosporine A in pediatric&#xD;
      and adolescent patients with stable renal graft function, reduces signs of&#xD;
      calcineurin-inhibitor toxicity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic transplant nephropathy is one of the major causes of graft loss after renal&#xD;
      transplantation. Toxicity of calcineurin-inhibitors is suspected to be one cause for loss of&#xD;
      graft function. Therefore reduction of cyclosporine A dosing can result in longer graft&#xD;
      survival and better graft function in patients after renal-transplantation. However,&#xD;
      reduction of immunosuppression can result in acute rejection episodes, although it is less&#xD;
      likely in patients with stable graft function 12 months or longer after successful renal&#xD;
      transplantation.&#xD;
&#xD;
      Therefore the aim of this randomized, controlled study in pediatric and adolescent renal&#xD;
      transplant recipients, is to compare the impact of reduced cyclosporine A-dosing to standard&#xD;
      CSA-dosing on renal graft function. Therapy monitoring in both groups will be performed by&#xD;
      obtaining CSA blood levels two hours after intake, as they provide an individual insight in&#xD;
      pharmacokinetics in comparison to conventional trough level (C0)-measurements.&#xD;
&#xD;
      Secondary objectives to evaluate are&#xD;
&#xD;
        1. the evaluation of the health-related Quality of life and psychosocial burden in the two&#xD;
           treatment arms.&#xD;
&#xD;
        2. measurement of the NFAT-regulated gene expression (nuclear factor of activated t-cells)&#xD;
           of intracellular cytokines [Interleukin-2, TNF-alpha, Interferon-gamma and GMCSF) by&#xD;
           quantitative PCR as measurement of CSA activity.&#xD;
&#xD;
        3. To obtain new insights by screening for metabolites conjunct with clinic features of&#xD;
           nephrotoxicity or graft rejections a metabolomic screening and a targeted analysis&#xD;
           (trimethylamine-N-oxide, neopterin and kynurenine/tryptophan ratio) will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment goals were not achieved. Extension of the trial concept had to be abjected due to&#xD;
    methodological reasons.&#xD;
  </why_stopped>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean decline per month in glomerular filtration rate (calculated acc. to Schwartz' formula) during the clinical trial - comparison between the two study arms (CSA-dose reduction group and group with constant CSA-dosing)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the NFAT-regulated gene expression (nuclear factor of activated t-cells) of intracellular cytokines [Interleukin-2, TNF-alpha, Interferon-gamma and GMCSF) by quantitative PCR as measurement of CSA activity</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of life evaluation using validated questionnaires (TACQoL) to determine differences between the two study arms</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Kidney Transplant</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard CSA-dosing without reduction. Therapy control by C2-monitoring.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reduction of cyclosporine A (CSA)-dosing</intervention_name>
    <description>Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age at inclusion 3-16 years&#xD;
&#xD;
          -  male or female patients&#xD;
&#xD;
          -  recipient of first or second renal transplant&#xD;
&#xD;
          -  graft age &gt; 24 months&#xD;
&#xD;
          -  last acute rejection episode &gt; 6 months ago&#xD;
&#xD;
          -  Immune suppression comedication Mycophenolatmofetil (MMF) in a dose range of 1200 +/-&#xD;
             200 mg/m² BSA/d within at least 6 months or minimal MPA-AUC ≥ 45 mg x h/l. If MPA-AUC&#xD;
             &lt; 45 mg x h/l adjustment of dosage with re-screening in ≥ 4 weeks is possible.&#xD;
&#xD;
          -  Application of CSA in stable dosing within the last 3 months before study inclusion&#xD;
             and CSA-C2-level &gt; 500 ng/ml. If CSA-C2-level &lt; 500 ng/ml adjustment of dosage with&#xD;
             re-screening in ≥ 4 weeks is possible.&#xD;
&#xD;
          -  steroid-free immunosuppression for at least 6 months before enrollment&#xD;
&#xD;
          -  biopsy of the renal graft without any signs of acute rejection (def. according to&#xD;
             BANFF classification), within 3 months before enrollment&#xD;
&#xD;
          -  written informed consent of parents/legal guardians and, if applicable, patient's&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  glomerular filtration rate &lt; 40 ml/min/1.73 m2 BSA (acc. to Schwartz' formula) at time&#xD;
             of enrollment&#xD;
&#xD;
          -  &gt; 2 episodes of acute graft rejection within 12 months prior to enrollment&#xD;
&#xD;
          -  condition after steroid-resistant graft rejection&#xD;
&#xD;
          -  actual participation in another clinical trial&#xD;
&#xD;
          -  Recurrence of primary renal disease in the graft&#xD;
&#xD;
          -  proven infection with EBV and/ or CMV and antiviral therapy within 3 months prior to&#xD;
             enrollment&#xD;
&#xD;
          -  proven infection with polyoma virus within 3 months prior to enrolment&#xD;
&#xD;
          -  pregnant or nursing women&#xD;
&#xD;
          -  hemoglobin &lt; 8 g/dl at screening visit&#xD;
&#xD;
          -  non-treated arterial hypertension&#xD;
&#xD;
          -  uncontrolled infectious disease&#xD;
&#xD;
          -  history of malignancy of any organ system, treated or non-treated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jörg Dötsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Pediatric Nephrology, University Hospital Erlangen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Pediatric Nephrology, University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Pediatric Nephrology, University Hospital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Pediatric Nephrology, University Hospital Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Pediatric Nephrology, University Hospital Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Pediatric Nephrology, University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Pediatric Nephrology, University Hospital Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Pediatric Nephrology, Community Hospital Memmingen</name>
      <address>
        <city>Memmingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Pediatric Nephrology, University Hospital Muenster</name>
      <address>
        <city>Muenster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Pediatric Nephrology, University Hospital München</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Pediatric Nephrology, University Hospital Rostock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>April 21, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2008</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney transplant recipients</keyword>
  <keyword>children and adolescents with kidney transplants</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

